A multicenter cross-sectional study on the evaluation of economic toxicity of anticancer drugs based on localized cost-prom

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038342

Enrollment

Unknown

Registered

2020-09-19

Start date

2021-05-01

Completion date

Unknown

Last updated

2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pathologically confirmed cancer patients, not limited to tumor type and stage

Interventions

case series:no intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with pathologically confirmed tumors, regardless of tumor type and stage, are expected to survive for more than 6 months; 2. Patients who are receiving or ending anti-tumor drug treatment for no more than 30 days are not limited to drugs and regimens (including chemotherapy drugs, molecular targeted drugs and immune checkpoint inhibitors); 3. Patients with clear consciousness and without cognitive impairment can understand and agree with the research requirements.

Exclusion criteria

Exclusion criteria: 1. Patients with no judgment or language communication disorder; 2. Patients who are not willing to cooperate with the investigation.

Design outcomes

Primary

Measure	Time frame
Chinese COST scale item score;EORTC QLQ-C30 score;	—

Secondary

Measure	Time frame
demographic;Disease specific factors;	—

Countries

China

Contacts

Public ContactJiang Qian

89529231@qq.com+86 13880419655

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026